Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Cladribine in the treatment of acute myeloid leukemia.

Robak T, Wierzbowska A.

Leuk Res. 2014 Apr;38(4):425-7. doi: 10.1016/j.leukres.2014.01.005. Epub 2014 Jan 14. No abstract available.

PMID:
24485872
2.

Cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) compared to standard induction in acute myeloid leukemia from myelodysplastic syndrome after azanucleoside failure.

Jaglal MV, Duong VH, Bello CM, Al Ali NH, Padron E, Fernandez HF, List AF, Lancet JE, Komrokji RS.

Leuk Res. 2014 Apr;38(4):443-6. doi: 10.1016/j.leukres.2013.12.010. Epub 2013 Dec 25.

PMID:
24439565
3.

A multicenter, open, non-comparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, and G-CSF as induction therapy in refractory acute myeloid leukemia - a report of the Polish Adult Leukemia Group (PALG).

Wrzesień-Kuś A, Robak T, Lech-Marańda E, Wierzbowska A, Dmoszyńska A, Kowal M, Hołowiecki J, Kyrcz-Krzemień S, Grosicki S, Maj S, Hellmann A, Skotnicki A, Jedrzejczak W, Kuliczkowski K; Polish Adult Leukemia Group.

Eur J Haematol. 2003 Sep;71(3):155-62.

PMID:
12930315
4.

Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group.

Wierzbowska A, Robak T, Pluta A, Wawrzyniak E, Cebula B, Hołowiecki J, Kyrcz-Krzemień S, Grosicki S, Giebel S, Skotnicki AB, Piatkowska-Jakubas B, Kuliczkowski K, Kiełbiński M, Zawilska K, Kłoczko J, Wrzesień-Kuś A; Polish Adult Leukemia Group.

Eur J Haematol. 2008 Feb;80(2):115-26. Epub 2007 Dec 11.

PMID:
18076637
5.

A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Polish Adult Leukemia Group.

Wrzesień-Kuś A, Robak T, Wierzbowska A, Lech-Marańda E, Pluta A, Wawrzyniak E, Krawczyńska A, Kuliczkowski K, Mazur G, Kiebiński M, Dmoszyńska A, Wach M, Hellmann A, Baran W, Hołowiecki J, Kyrcz-Krzemień S, Grosicki S; Polish Adult Leukemia Group.

Ann Hematol. 2005 Sep;84(9):557-64. Epub 2005 Apr 27.

PMID:
15856358
6.
7.

Treatment of myelodysplastic syndromes with AML-type chemotherapy.

Estey E, Pierce S, Kantarjian H, O'Brien S, Beran M, Andreeff M, Escudier S, Koller C, Kornblau S, Robertson L, et al.

Leuk Lymphoma. 1993;11 Suppl 2:59-63. No abstract available.

PMID:
7510196
9.

Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951.

Wells RJ, Adams MT, Alonzo TA, Arceci RJ, Buckley J, Buxton AB, Dusenbery K, Gamis A, Masterson M, Vik T, Warkentin P, Whitlock JA; Children's Cancer Group Study 2951.

J Clin Oncol. 2003 Aug 1;21(15):2940-7.

PMID:
12885813
10.

[Chemotherapy of relapsed AML and ALL].

Nishikawa K.

Rinsho Ketsueki. 1996 Aug;37(8):647-50. Review. Japanese. No abstract available.

PMID:
8827871
11.

Low dose of homoharringtonine and cytarabine combined with granulocyte colony-stimulating factor priming on the outcome of relapsed or refractory acute myeloid leukemia.

Gu LF, Zhang WG, Wang FX, Cao XM, Chen YX, He AL, Liu J, Ma XR.

J Cancer Res Clin Oncol. 2011 Jun;137(6):997-1003. doi: 10.1007/s00432-010-0947-z. Epub 2010 Dec 9.

PMID:
21152934
12.

Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.

Walker AR, Komrokji RS, Ifthikharuddin J, Messina P, Mulford D, Becker M, Friedberg J, Oliva J, Phillips G, Liesveld JL, Abboud C.

Leuk Res. 2008 Dec;32(12):1830-6. doi: 10.1016/j.leukres.2008.04.026. Epub 2008 Jun 20.

PMID:
18571721
13.

Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes.

Borthakur G, Huang X, Kantarjian H, Faderl S, Ravandi F, Ferrajoli A, Torma R, Morris G, Berry D, Issa JP.

Leuk Lymphoma. 2010 Jan;51(1):73-8. doi: 10.3109/10428190903318329.

14.

Salvaging AML with CLAG: novel option, or more of the same?

Wei A, Teh TC.

Leuk Res. 2011 Mar;35(3):297-8. doi: 10.1016/j.leukres.2010.10.015. Epub 2010 Nov 11. No abstract available.

PMID:
21074270
15.
16.

A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome.

Wei G, Ni W, Chiao JW, Cai Z, Huang H, Liu D.

J Hematol Oncol. 2011 Nov 14;4:46. doi: 10.1186/1756-8722-4-46. Review.

17.

Treatment of acute myeloid leukemia and myelodysplastic syndrome with orally administered cytarabine ocfosfate and granulocyte colony-stimulating factor.

Okumura H, Yoshida T, Takamatsu H, Katoh T, Murashima M, Watanabe A, Yamauchi H, Matano S, Chuhjo T, Takeshima M, Kaya H, Ohtake S, Nakamura S, Matsuda T.

Int J Hematol. 1997 Apr;65(3):263-8.

PMID:
9114597
18.

Mito-flag as salvage therapy for relapsed and refractory acute myeloid leukemia.

Hänel M, Friedrichsen K, Hänel A, Herbst R, Morgner A, Neser S, Nicklisch M, Teich M, Ehninger G, Fiedler F.

Onkologie. 2001 Aug;24(4):356-60.

PMID:
11574763
20.

Difficulty of peripheral blood stem cell collection after multiple consolidation therapy in acute myeloid leukemia.

Narimatsu H, Yamamoto F, Kurahashi S, Sugimoto T, Sugiura I.

J Clin Exp Hematop. 2008 Apr;48(1):29-31. No abstract available.

Supplemental Content

Support Center